Xiaoyan Pan,Jian Shi,Xue Hu,Yan Wu,Liang Zeng,Yanfeng Yao,Weijuan Shang,Kunpeng Liu,Ge Gao,Weiwei Guo,Yun Peng,Shaohong Chen,Xiaoxiao Gao,Cheng Peng,Juhong Rao,Jiaxuan Zhao,Cheng Gong,Hui Zhou,Yudong Lu,Zili Wang,Xiliang Hu,WenJuan Cong,Lijuan Fang,Yongxiang Yan,Jing Zhang,Hui Xiong,Jizu Yi,Zhiming Yuan,Pengfei Zhou,Chao Shan,Gengfu Xiao

Abstract:Abstract The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates